Infants less than 1 year of age at diagnosis of acute lymphoblastic leukemia (ALL) have a poor prognosis, which has been attributed primarily to a breakpoint in chromosomal band 11q23 or the MLL gene. Most infants with an 11q23 breakpoint have a t(4;11)(q21;q23). We studied the cytogenetics of the leukemia cells of 56 infants on CCG-1883, a single-arm clinical treatment protocol for infant ALL. Twenty-one patients had t(4;11)(q21;q23), seven had other rearrangements with breakpoints in 11q23 (other 11q23), 16 had normal chromosomes, two had t(1;19)(q32;p13), one had Ͼ50 chromosomes, and nine had non-recurring structural abnormalities. To determine whether there is a difference in outcome for infants with t(4;11), other 11q23 and the remaining patients, we compared eventfree survival (EFS) and other clinical and laboratory features of the above infants. Infants without t(4;11) and those with other 11q23 rearrangements had significantly better EFS than those with t(4;11) (P = 0.007 and P = 0.02, respectively). t(4;11) correlated with age less than 6 months and with CD10 negativity, both of which also were poor prognostic indicators. After adjustment for age, there was still a significant difference in EFS between patients with t(4;11) and those with other 11q23 rearrangements (P = 0.02), and between patients with t(4;11) and those without t(4;11) (P = 0.04). Among CD10 negative patients, t(4;11) was associated with a worse EFS (P = 0.01). Multivariate analysis showed that after adjusting for a variety of clinical and laboratory features, t(4;11) was the most important prognostic factor for poor outcome, and patients with other 11q23 rearrangements had as good an outcome as the remaining patients without t(4;11).
Introduction
The karyotypes of infants less than 1 year of age at diagnosis of acute lymphoblastic leukemia (ALL) differ from those of children at least 1 year of age at diagnosis. Most infant patients with ALL are near-diploid (45-47 chromosomes) with structural abnormalities and a high frequency of 11q23 rearrangements, and very few have the high hyperdiploidy (Ͼ50 chromosomes) associated with a good prognosis. Moreover, infants with ALL have a poor prognosis compared with ALL in children у1 year of age at diagnosis, and much of the poor outcome has been attributed to a breakpoint in chromosomal band 11q23, [1] [2] [3] [4] [5] which occurs in approximately 50% of infants with ALL studied by cytogenetic analyses 1, [6] [7] [8] and approximately 75% studied by molecular techniques. 4, 6, [8] [9] [10] [11] Although deletions, inversions and unbalanced translocations are found, the 11q23 breakpoint usually occurs as part of a reciprocal translocation, with many different 11q23 partner chromosomes described, the most common being t(4;11)(q21;q23), occurring in 30-45% of infants when studied by chromosomal analysis. 1, 3, 5 Correspondence: NA Heerema, Children's Cancer Group, PO Box 60012, Arcadia, CA 91066-6012, USA; Fax: 626 445 4334 Received 17 August 1998; accepted 10 February 1999 Both cytogenetic and molecular analyses have been used to determine the presence and prognostic significance of 11q23 aberrations in infant ALL. Molecular studies of MLL, the gene involved in most 11q23 rearrangements, 4 show that approximately 70% of infants have rearranged MLL and that abnormal MLL correlates with a poor outcome. [2] [3] [4] However, few of these studies could discriminate among MLL partner genes. In one study, Taki et al 8 showed that of 24 infants with ALL who had MLL rearrangements by Southern analysis 2/11 (18.2%) with t(4;11) and 5/13 (38.5%) with other 11q23 rearrangements were in continuous remission. On the other hand, in a cohort of 16 infants with ALL and cytogenetic abnormalities of 11q23, five with t(4;11)(q21;q23), and 11 with other rearrangements, Behm et al 12 found that 14 had rearrangements of MLL, and that there was no difference in outcome for those infants with t(4;11) vs those with other 11q23 rearrangements. These studies and others suggest that germline MLL defines a subset of infant ALL which may have a good prognosis. [2] [3] [4] 8, 11, 12 However, since most studies of MLL/11q23 rearrangements do not differentiate between t(4;11)(q21;q23) and other MLL/11q23 rearrangements, the significance of the specific rearrangement of MLL/11q23 is not understood.
In a previous CCG study of infant ALL, CCG-107, we examined the influence of an 11q23 breakpoint in general, as well as the specific t(4;11)(q21;q23), on event-free survival (EFS). We showed that in CCG-107, patients with a t(4;11) had a worse EFS than patients with other abnormalities of 11q23, but numbers were small and statistical significance was not met (P = 0.09). 1 We now report the cytogenetics of the CCG-107 successor study, CCG-1883. 13 CCG-1883 had the same eligibility criteria as CCG-107. In CCG-1883, both patients with other abnormalities of 11q23 and those with normal 11q23 had similar EFS of 57.1% and 44.6%, respectively, at 60 months; however, patients with t(4;11) had a 4.8% EFS at 60 months, which was significantly different from the other patients (P = 0.0007).
Materials and methods

Cytogenetic analyses
Between 20 December 1988 and 25 August 1993, CCG institution patients less than 1 year of age at diagnosis of ALL were eligible for CCG-1883. Cytogenetic analyses of bone marrow or unstimulated peripheral blood at diagnosis, prior to treatment, were done at local institutions, and karyotypes from at least two cells of each abnormal clone or of normal cells in cases of normal cytogenetics were centrally reviewed by at least two members of the CCG Cytogenetics Committee. All cases were banded, and a minimum band level of 400 bands was required for acceptance. An abnormal clone was defined according to the Second International Workshop, 14 and kary-otypes were designated according to the ISCN (1995). 15 Acceptance of a normal case required complete analysis of a minimum of 20 banded metaphases. Normal unstimulated peripheral blood analyses were not accepted, as the abnormal clone could have been missed.
Treatment
Treatment consisted of four-drug (vincristine, prednisone, Lasparaginase and daunomycin) induction. Consolidation therapy included high-dose cytarabine, vincristine and L-asparaginase followed by very high-dose systemic methotrexate with leukovorin rescue as CNS preventive therapy and subsequent intrathecal methotrexate. A 4-week interim maintenance of intravenous methotrexate (100 mg/m 2 ) and L-asparaginase was followed by a 10-week intensification phase consisting of reinduction and reconsolidation. Standard maintenance consisted of daily 6-mercaptopurine, weekly methotrexate, and monthly vincristine and prednisone pulses with intrathecal methotrexate for a total duration of therapy of 2 years for females and 3 years for males. Effective CNS preventive therapy was accomplished without cranial irradiation, using highdose systemic methotrexate and cytarabine and periodic intrathecal administration of the same two agents. Details of the treatment protocol have been described. 13 
Statistical methods
The infants with cytogenetic evaluation were evaluated for similarity of various clinical, demographic, and laboratory features using 2 tests for homogeneity of proportions comparing the three primary groups of t(4;11)(q21;q23), other 11q23 aberrations, and the remaining patients (normal 11q23). Most of the outcome analyses used life table methods and associated statistics. Life table estimates were calculated by the Kaplan-Meier (KM) procedure and the standard deviation of the life table estimate was obtained using Greenwood's formula. 16 In the presentation of results, the KM estimate and its standard deviation at selected important time points are sometimes provided. An approximate 95% confidence interval would be obtained by using the life table estimate ± 1.96 standard deviations. The primary endpoint examined was event-free survival (EFS) from entry on study. EFS events included induction failure (non-response to therapy or death during induction), leukemic relapse at any site, death during remission, or second malignant neoplasm, whichever occurred first. Patients not experiencing an event at the time of analysis were censored in the EFS analysis at the time of their last contact. Since cytogenetic results were not available for a large group of patients in CCG-1883, the patients who had cytogenetic evaluation were compared with those who did not have cytogenetic evaluation with respect to clinical features, laboratory results, and disease outcome.
Life table comparisons of EFS outcome pattern for patient groups generally used the log rank statistic. 17, 18 Stratified log rank tests were sometimes used to adjust for the possible modifying effect of other factors on the comparison of interest. 18, 19 P values for life table comparisons are based on the pattern of outcome across the entire period of patient follow-up, although life table estimates at specific time values may be given for comparative purposes. For purposes of comparison, P values that are р0.05 are referred to as significant differences and P values that are between 0.05 and 0.10 are referred to as showing borderline significance. Cox regression analysis was used to adjust for important patient prognostic characteristics in a multivariate analysis of the effect of t(4;11)(q21;q23) and other 11q23 abnormalities when adjusted for other factors. 20 Cox regression significance levels were based on the likelihood ratio test. Estimates of the life table relative hazard rate (RHR) were calculated by the O/E method for log rank analyses and using the exponentiated regression coefficient for Cox regression.
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Results
There were 135 patients entered on CCG-1883. Cytogenetic results from 56 (41.5%) were accepted after review and are presented in Table 1 . Forty patients (71.4%) had an abnormal karyotype. A t(4;11)(q21;q23) or variant with the same breakpoints (combined as t(4;11) hereafter) was present in 21 patients (37.5%, Pts 17-37), 20 of whom have had an event. Seven additional patients (12.5%, Pts 38-44) had other chromosomal aberrations with breakpoints in 11q23, four of whom (Pts 38-40) had t(11;19)(q23;p13) or a variant (Pt 41); two experienced events. Four of the seven patients with another 11q23 rearrangement have not had an event. Two patients (3.5%, Pts 45 and 46) had a t(1;19)(q23;p13); both failed. Three patients (5.4%, Pts 48-50) had a breakpoint in 15q13; none has failed. One patient (1.8%, Pt 56) had hyperdiploidy with Ͼ50 chromosomes and was the only patient with abnormal chromosomes that did not have a structural abnormality. This patient relapsed at 3 years. Three patients had 45 chromosomes with structural abnormalities (Pts 50, 53, 54), two have had events. Two patients were pseudodiploid (Pts 51 and 52); one was lost to follow-up and the other relapsed. One patient had a marker chromosome as the sole abnormality (Pt 55) and is in continuous remission. Sixteen patients (28.6%) had normal chromosomes, eight of whom had an event.
Nine of the 56 patients with accepted cytogenetic analyses underwent bone marrow transplantation (BMT) in first remission, six t(4;11), two other 11q23 and one patient with normal chromosomes. Eight of these patients had events, five deaths as initial events and three relapses. The sole patient not experiencing an event post-BMT was a t(4;11) patient.
Event-free survival (EFS) for patients with accepted cytogenetic analyses showed no statistically significant difference from that of patients without accepted cytogenetic analyses (30% and 45%, respectively, P = 0.24). The only significant differences in clinical characteristics between patients with and those without accepted cytogenetic analyses were a higher frequency of L2 French-American-British (FAB) classification in patients without accepted cytogenetic results and a higher percentage of non-white/non-black 'other' race patients. None of the nine patients with L2 FAB had accepted cytogenetic analyses, and eight of the nine had events. To examine the effect of uneven distribution of FAB, outcome for those with and without cytogenetic evaluation was compared with stratification for FAB results. While the results did not reach a conventional significance criterion, the P value was marginally significant (P = 0.07).
Patients with t(4;11) had a significantly lower EFS at 60 months than patients without t(4;11) (4.8% and 46.5%, respectively, P = 0.007). EFS among patients with t(4;11), other 11q23, and normal 11q23 also was significantly different (P = 0.003 for overall log rank test, Figure 1) . Comparison of the t(4;11) group with the normal 11q23 group was signifi- EFS for patients with normal 11q23 (------), patients with other 11q23 (----), and patients with t(4;11)(q21;q23) (---).
cant at a P = 0.003 level (RHR = 2.60 times higher). Importantly, EFS also was significantly different between patients with t(4;11) and those with other 11q23 (P = 0.01, RHR = 4.00).
To evaluate the possibility that other clinical and/or biologic factors were operational in the poor outcome of patients with t(4;11), we compared the following variables which were available on all patients entered on this study: age, white blood cell count (WBC) at diagnosis, gender, race, massive organomegaly, FAB morphology, immunophenotype, and early response to therapy (assessed by per cent blasts in the marrow on day 7, Table 2 ). In general, the cytogenetic groups were similar with respect to most characteristics, but differed with regard to three factors: age, WBC and immunophenotype.
Patients with t(4;11) tended to be younger than those without this translocation; 67% of patients with t(4;11) were Ͻ6 months at diagnosis while only 23% of patients without t(4;11) were Ͻ6 months of age (P = 0.001). The t(4;11) patients were significantly younger than the patients with normal 11q23 (P = 0.003), and reached a marginally significant level compared with the other 11q23 group (P = 0.10). In this study of patients with cytogenetic evaluation, the younger infants (Ͻ6 months at diagnosis) had a much worse EFS outcome (P = 0.007, RHR = 2.33), as also was seen in the entire CCG-1883 study (P = 0.0006, RHR = 2.13). 13 Importantly, after stratified adjustment for age, there was still a statistically significant difference in EFS between patients with t(4;11) and those with other 11q23 (P = 0.02) and between patients with t(4;11) and those without t(4;11) (P = 0.04). The major contribution of the difference came from the older subgroup, age у6 months (P = 0.02), and there was no statistically significant difference for the younger age subgroup (EFS for t(4;11) = 0%, for other 11q23 = 50%, and for normal 11q23 = 17%, P = 0.36). For infants у6 months at diagnosis, the patient numbers were small, but the P value reached a marginal significance level, and the curves clearly suggest a better outcome for the other 11q23 and the normal 11q23 groups than the t(4;11) group (EFS = 60%, 52% and 14%, respectively, P = 0.07; Figure 2 ). The differences between age subgroups n, number of patients; massive hepatomegaly/splenomegaly, palpable at the level of the umbilicus; WBC, white blood cell count/10 −3 ml; HGB, hemoglobin; Platelet, platelet count/10 −3 ml; FAB, French-American-British classification; D7M, day 7 marrow; M1, Ͻ5% blasts; M2, 5-25% blasts; M3, Ͼ25% blasts; NA = not applicable.
Figure 2
EFS for patients у6 months of age at diagnosis with normal 11q23 (------), patients with other 11q23 (----) , and patients with t(4;11)(q21;q23) (---).
were not significant after adjustment for the presence of t(4;11) (P = 0.29), although there was a suggestion of a better outcome for older infants in the patients who did not have t(4;11) (P = 0.12, RHR = 2.13). Of interest, when one examines just the patients with 11q23 abnormalities and compares age groups after stratification for either t(4;11) or other 11q23 status, there was no suggestion of any age effect (P = 0.92). Thus, any age effect on prognosis was confined to the patients without 11q23 abnormalities.
The t(4;11) group and the other 11q23 group had significantly higher WBC counts at diagnosis than the normal 11q23 group (P = 0.02 and P = 0.03, respectively). All t(4;11) and other 11q23 patients were CD10 negative, although 77% of the normal 11q23 group were CD10 + (P = 0.0001 and P = 0.003, respectively). CCG-1883 CD10 positive patients had a much better EFS than CD10 negative patients (EFS = 56% and 30%, respectively, P = 0.002). After adjustment for CD10, there was still a statistically significant difference in EFS between patients with t(4;11) and those without t(4;11) (P = 0.01), with the major contribution from the CD10 negative subgroup. Additionally, 72% of the t(4;11) patients and 67% of the other 11q23 patients were CD24 negative, whereas none of the patients with normal 11q23 was CD24 negative (P = 0.001).
Since there was a strong correlation of important prognostic factors such as age, WBC, CD10 and t(4;11) status, a multivariate Cox regression was performed to adjust for these and 683 other patient factors simultaneously. That analysis found that the cytogenetic grouping factor (t(4;11), other 11q23, and normal 11q23) had the most important predictive influence on EFS outcome (P = 0.01), and no other factors reached significance in the regression after cytogenetic group was included.
Discussion
As in other studies of infant ALL, we found a unique cytogenetic profile in our patients. Fifty-five patients (98%) were near-diploid (45-47 chromosomes), and only one patient had Ͼ50 chromosomes. Overall, patients with high hyperdiploidy have a good prognosis, although our patient with high hyperdiploidy relapsed at 3 years. Sixteen patients (29%) had normal chromosomes by cytogenetic analysis. It is possible that some of these patients had molecular rearrangements of MLL or other genes that were not detected by classic cytogenetic analyses; however, as only eight of these patients failed, the frequency of an undetected t(4;11) in these patients is most likely low. Eight of the 56 patients reported in this study were examined for MLL rearrangement molecularly, 2 six had rearranged MLL, five t(4;11) patients and one t(11;19) patient. Five of the patients with rearranged MLL had an event. The patient with t(11;19) remains in first remission. It has been shown that both t(4;11) and t(11;19) involve the MLL gene, 8, 12 and our results are consistent with that observation. There were two patients with germline MLL, one patient with normal chromosomes who is in first remission, and the patient with HeH, who relapsed at 3 years.
In this study, EFS for infants with the specific translocation, t(4;11)(q21;q23), was significantly worse than EFS for infants with other 11q23 abnormalities or with normal 11q23. EFS for infants with another rearrangement of 11q23 or normal 11q23 is 46.5% at 60 months of follow-up, which is significantly better than EFS for patients with t(4;11)(q21;q23), whose EFS is 4.8% at 60 months (P = 0.007). This confirms our earlier observations in CCG-107 that infants with an 11q23 rearrangement but not t(4;11)(q21;q23) or variant thereof have a better EFS than patients with a t(4;11). 1 It also confirms previous cytogenetic and molecular studies showing that infants with normal MLL or 11q23 have a good prognosis. [2] [3] [4] 8, 11 The normal function of MLL is unknown, although its structural components suggest that it either directly interacts with DNA and/or interacts with other DNA-binding proteins. 22 The MLL breakpoints in patients with different 11q23 translocations tend to cluster in the breakpoint cluster region, an 8.5 kb region between exons 5 and 11, 23, 24 and most chimeric genes contain similar MLL gene contributions, encoding the amino terminal region including only the AT hooks and the methyltransferase. AF4, the chromosome 4 gene involved in the t(4;11)(q23;q21), is a serine-proline-rich gene which is ubiquitously expressed and localizes to the nucleus, [25] [26] [27] but neither its normal function nor the presumed role it plays in transformation in t(4;11) leukemia is understood.
The proteins encoded by most 11q23 partner genes appear to bear little or no homology to each other, 28 and may encode different types of functional elements, with the resultant chimeric proteins operating in distinct ways in leukemogenesis. 22, 28 As MLL may interact with DNA or other DNA-binding proteins, the various chimeric proteins may activate or repress distinct genes, resulting in diverse leukemias, 29 with different responses to treatment and therefore dissimilar outcomes. Some 11q23 translocations are specific to ALL, others to AML, and others occur in both ALL and AML. The t(4;11) occurs in ALL, but the cells frequently have myeloid features. 30 Both t(11;19)(q23;p13.1) and t(6;11)(q27;q23) appear to be specific to AML, 31, 32 and t(9;11)(p22;q23) occurs in both ALL and AML. 1, 33 A specific type of leukemia as a result of the MLL partner chromosome is also suggested by 'knock-in' mouse studies in which chimeric mice with MLL-AF9 develop acute myeloid leukemia, whereas mice with an MLL-MYC fusion do not. 34 Additionally, different outcomes have been reported as a result of specific partners of 11q23 in pediatric AML, where patients with acute monocytic leukemia and t(9;11)(p22;q23) have a longer survival than patients with AML and other 11q23 translocations. 7 Our results indicate that identification of 11q23 partner chromosomes is also important in determining the prognosis for infants with 11q23 ALL, and that the t(4;11)(q21;q23) is associated with a poor EFS in infants.
CCG-1883 patients with t(4;11) tended to be younger at diagnosis than patients with either other 11q23 rearrangements or with normal 11q23. Only infants у6 months of age with t(4;11) had a worse EFS than those without t(4;11). However, even after adjustment for age, there was a statistically significant difference in EFS between patients with t(4;11) and those with other 11q23 abnormalities (P = 0.02). Additionally, the difference between EFS for infants Ͻ6 months and those у6 months was not significant after adjustment for the presence vs the absence of t(4;11) (P = 0.29), or for any 11q23 breakpoint (t(4;11) and other 11q23, P = 0.92). The high frequency of t(4;11) in infants Ͻ6 months of age is similar to that reported in previous studies. 1, 3, 4 In one molecular study, MLL was rearranged in 92% of ALL in infants Ͻ6 months, but in only 50% of infants 6-12 months of age. 35 The biological etiology of the high frequency of t(4;11) in very young ALL patients is not understood, and it has been hypothesized that an in utero event is responsible. 36, 37 However, the nature of that event is not known.
In this study, infants with t(4;11) did not differ from infants with other 11q23 rearrangements in presenting clinical characteristics other than age. WBC counts were significantly higher in both 11q23 subgroups compared with patients with normal 11q23. No patients in either the t(4;11) or other 11q23 groups were CD10 positive, while 77% of patients with normal 11q23 were CD10 positive.
Interestingly, 83% of t(4;11) infants exhibited an early response to therapy, as evidenced by an M1 marrow on day 7. This is in contrast to 33% of other 11q23 infants (P = 0.04) and 58% of normal 11q23 infants (P = 0.50). Early response to therapy has been shown to be a favorable prognostic indicator in most other ALL patient groups, 38 although we found that Philadelphia (Ph) chromosome-positive and -negative patients had similar response to induction therapy, but Ph+ patients had a significantly worse EFS, 39 indicating that early response to therapy is not always associated with a better outcome. Thus, although the t(4;11) ALL infants exhibit rapid response to induction therapy, the leukemia cells ultimately show resistance to current therapy modalities, and relapse occurs.
As shown in Table 1 , one t(4;11), two t(11;19), one del(11) and one ins(11;5) patients have not had an event. Other studies have suggested that patients with t(11;19) may have a very poor prognosis; 40,41 our study does not confirm those observations, although numbers are very small. It has also been reported that balanced rearrangements with 11q23 breakpoints tend to have rearranged MLL, while unbalanced rearrangements do not. 8, 12, 42 Only one of the other 11q23 CCG-1883 infants had an unbalanced rearrangement, del(11)(q23), and this patient is in continuous remission.
Molecular studies of MLL rearrangements of the other 11q23 cytogenetic aberrations, except one patient with t(11;19), were not done. The cytogenetic data reported here indicate that further cytogenetic, molecular and clinical studies of larger numbers of 11q23 patients are necessary to clearly define the prognostic impact of various 11q23 and MLL rearrangements in infant ALL.
In conclusion, this study confirms our previous observations that infants with t(4;11)(q21;q23) have a significantly worse EFS than infants with other 11q23 rearrangements or normal 11q23. Although many important prognostic features for infant ALL are highly correlated with one another, multivariate analysis indicates that cytogenetic group, t(4;11), other 11q23, and normal 11q23, has the greatest predictive influence for EFS. Once adjusted for this factor, the other clinical and laboratory patient characteristics failed to have significant prognostic effect. This suggests that identification of the 11q23 partner chromosome is important in determining treatment strategies for infants with 11q23 ALL.
